Nazari P, Golnari P, Hurley M C, Shaibani A, Ansari S A, Potts M B, Jahromi B S
From the Departments of Neurological Surgery and Radiology Northwestern Memorial Hospital, Northwestern University Feinberg School of Medicine, Chicago, Illinois.
From the Departments of Neurological Surgery and Radiology Northwestern Memorial Hospital, Northwestern University Feinberg School of Medicine, Chicago, Illinois
AJNR Am J Neuroradiol. 2021 Jul;42(7):1264-1269. doi: 10.3174/ajnr.A7108. Epub 2021 Apr 1.
Published data regarding embolic protection device efficacy is mixed, and its use during carotid artery stent placement remains variable. We, therefore, examined the frequency of embolic protection device use and its association with outcomes after carotid artery stent placement using a national quality improvement data base.
Patients undergoing carotid artery stent placement with or without embolic protection devices were identified in the American College of Surgeons National Surgical Quality Improvement Program data base. The primary outcome was the incidence of major adverse cardiovascular events (defined as death, stroke, or myocardial infarction/arrhythmia) within 30 days. Propensity scoring was used to create 2 matching cohorts of patients using demographic and baseline variables.
Between 2011 and 2018, among 1200 adult patients undergoing carotid artery stent placement, 23.8% did not have embolic protection devices. There was no trend toward increased embolic protection device use with time. Patients without embolic protection device use received preoperative antiplatelets less frequently (90.6% versus 94.6%, = .02), underwent more emergent carotid artery stent placement (7.2% versus 3.6%, = .01), and had a higher incidence of major adverse cardiovascular events (OR = 1.81; 95% CI, 1.11-2.94) and stroke (OR = 3.31; 95% CI, 1.71-6.39). After compensating for baseline imbalances using propensity-matched cohorts ( = 261 for both), carotid artery stent placement without an embolic protection device remained associated with increased major adverse cardiovascular events (9.2% versus 4.2%; OR = 2.30; 95% CI, 1.10-4.80) and stroke (6.5% versus 1.5%; OR = 4.48; 95% CI, 1.49-13.49).
Lack of embolic protection device use during carotid artery stent placement is associated with a 4-fold increase in the likelihood of perioperative stroke. Nevertheless, nearly one-quarter of patients in the American College of Surgeons National Surgical Quality Improvement Program underwent unprotected carotid artery stent placement. Efforts targeting improved embolic protection device use during carotid artery stent placement are warranted.
关于栓塞保护装置疗效的已发表数据不一,其在颈动脉支架置入术中的使用情况仍存在差异。因此,我们使用全国质量改进数据库,研究了栓塞保护装置的使用频率及其与颈动脉支架置入术后结局的关联。
在美国外科医师学会国家外科质量改进计划数据库中,识别接受或未接受栓塞保护装置的颈动脉支架置入患者。主要结局是30天内发生主要不良心血管事件(定义为死亡、卒中或心肌梗死/心律失常)的发生率。使用倾向评分法,根据人口统计学和基线变量创建两组匹配的患者队列。
在2011年至2018年期间,1200例接受颈动脉支架置入的成年患者中,23.8%未使用栓塞保护装置。栓塞保护装置的使用没有随时间增加的趋势。未使用栓塞保护装置的患者术前接受抗血小板治疗的频率较低(90.6%对94.6%,P = 0.02),接受急诊颈动脉支架置入的比例更高(7.2%对3.6%,P = 0.01),主要不良心血管事件(OR = 1.81;95%CI,1.11 - 2.94)和卒中(OR = 3.31;95%CI,1.71 - 6.39)的发生率更高。使用倾向匹配队列(两组均为P = 261)校正基线不平衡后,未使用栓塞保护装置的颈动脉支架置入术仍与主要不良心血管事件增加相关(9.2%对4.2%;OR = 2.30;95%CI,1.10 - 4.80)和卒中(6.5%对1.5%;OR = 4.48;95%CI,1.49 - 13.49)。
颈动脉支架置入术中未使用栓塞保护装置与围手术期卒中风险增加4倍相关。然而,在美国外科医师学会国家外科质量改进计划中,近四分之一的患者接受了未使用保护装置的颈动脉支架置入术。有必要致力于提高颈动脉支架置入术中栓塞保护装置的使用。